Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensitrelvir - Shionogi

Drug Profile

Ensitrelvir - Shionogi

Alternative Names: Ensitrelvir fumarate - Shionogi; Ensitrelvir fumaric acid - Shionogi; S-217622; SARS-CoV2 3C-like protease inhibitor - Shionogi; Xocova

Latest Information Update: 19 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hokkaido University; Shionogi
  • Developer Juniper Therapeutics; Shionogi
  • Class Amines; Antivirals; Chlorine compounds; Fluorobenzenes; Indazoles; Ketones; Small molecules; Triazines; Triazoles
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Clinical Phase Unknown Post acute COVID 19 syndrome

Most Recent Events

  • 24 May 2024 Shionogi terminates phase III trial in COVID-1029 infections in US, Argentina, Brazil, Colombia, Ghana, India, Kenya, Malawi, Mexico, Pakistan, Philippines, Poland, South Africa, Thailand, Turkey, Uganda and Japan (PO) (NCT05305547)
  • 06 Mar 2024 Chemical structure information added
  • 05 Mar 2024 Launched for COVID-2019 infections in Japan (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top